PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Cell and Gene Therapy

Upcoming Events

SLAS Europe – 7th April 2025
PEGS Boston – 17/02/2025
Biotechnology Show 2025: 20th January 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025

Stem cell therapy offers potential for thalassemia patients to have fewer blood transfusions, says GlobalData

The possibility of using hematopoietic stem cells to restore production of normal hemoglobin is being investigated as a potential strategy to reduce the number of blood transfusions for thalassemia patients.

Magdalene Crabbe, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view:

“In clinical trials, stem cells from the bone marrow of thalassemia patients with the normal form of the HBB gene were transfected through a viral vector into their erythrocytes. The majority of patients (68.2%) no longer required monthly blood transfusions.

“Despite the positive trial results, the procedure is expensive and questions remain over the long-term effects of stem cell therapy on people with hematological disorders.

“Most thalassemia patients need regular transfusions to supply them with red blood cells that can carry enough oxygen, which can improve the patient’s prognosis. However this can result in a multitude of complications.

“Continued research efforts are needed to find ways to improve the life expectancy of these patients, and to also give them the opportunity to enjoy energetic activities that require the correct functionality of oxygen homeostasis machinery.”

Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Eppendorf – 18.03.2025
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025